MintHealth

minthealth.io

MintHealth enables companies to achieve intended health and economic outcomes with their existing products/services through a universal user rewards and redemption marketplace.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

RIBBON BIOLABS ESTABLISHES IP PORTFOLIO WITH FIRST GRANTED U.S. PATENT COVERING FAST, COST-EFFECTIVE, LONG DNA SYNTHESIS TECHNOLOGY

Ribbon Biolabs | July 20, 2022

news image

Ribbon Biolabs, the DNA synthesis company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs’ novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications to be granted to the company, forming the foundation of its IP portfolio covering its long DNA synthesis technology. “ Read More

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

news image

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More

INDUSTRIAL IMPACT

MINDMED ANNOUNCES TRANSITIONS TO MANAGEMENT TEAM

Mind Medicine (MindMed) Inc. | December 30, 2021

news image

Mind Medicine Inc. a leading biotech company developing psychedelic-inspired therapies, announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. "On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors. We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under...

Read More

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

news image

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More
news image

INDUSTRIAL IMPACT

RIBBON BIOLABS ESTABLISHES IP PORTFOLIO WITH FIRST GRANTED U.S. PATENT COVERING FAST, COST-EFFECTIVE, LONG DNA SYNTHESIS TECHNOLOGY

Ribbon Biolabs | July 20, 2022

Ribbon Biolabs, the DNA synthesis company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs’ novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications to be granted to the company, forming the foundation of its IP portfolio covering its long DNA synthesis technology. “ Read More

news image

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More
news image

INDUSTRIAL IMPACT

MINDMED ANNOUNCES TRANSITIONS TO MANAGEMENT TEAM

Mind Medicine (MindMed) Inc. | December 30, 2021

Mind Medicine Inc. a leading biotech company developing psychedelic-inspired therapies, announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. "On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors. We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under...

Read More
news image

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More